Telomere-based therapy for immunosenescence

Trends in Immunology

Volumn 23, Issue 4, 2002, Pages 175-176

  Lord, Janet M ^a   Akbar, Arne N ^b   Kipling, David ^c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN;

AGED; AGING; CELL SURVIVAL; CONFERENCE PAPER; GENE THERAPY; HUMAN; IMMUNE DEFICIENCY; IMMUNE SYSTEM; LYMPHOCYTE CLONE; LYMPHOCYTE PROLIFERATION; SENESCENCE; T LYMPHOCYTE; TELOMERE;

AGED; AGING; GENE THERAPY; HUMANS; TELOMERE;

EID: 0036533491     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4906(02)02170-1     Document Type: Conference Paper

References (8)

1. Telomere fluorescence measurements in granulocytes and T-lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood
2. Transfer of the human telomerase reverse transcriptase (TERT) gene into T lymphocytes results in extension of replicative potential
3. Immortalization of human CD8(+) T-cell clones by ectopic expression of telomerase reverse transcriptase
4. Limited telomere shortening in hematopoietic stem cells after transplantation
5. The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability
6. Human T-cell clones in long-term culture as a model of immunosenescence
7. + T cells by fluorescent in situ hybridisation
8. Control of telomere length by the human telomeric protein TRF1